Publications
The value of fast diagnostics in time-critical infections
20 April 2026
Advancing earlier intervention in time‑critical infections Sepsis continues to…
Evaluating novel antimicrobials within EU joint clinical assessments
16 April 2026
Antimicrobial resistance (AMR) is a growing global health and economic threat.…
The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases
31 March 2026
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity…
The case for adopting a broader perspective on value in Health Technology Assessment
3 March 2026
In this Whitepaper, we describe different perspectives that can be adopted in…
Insights
Valuing patient and carer time in HTA: equity and opportunity cost
15 May 2026
We address two criticisms of valuing patient and carer time in HTA: that it…
Is the revised Congressional Budget Office model of new drug development fit for purpose?
6 May 2026
As U.S. drug-pricing policy changes accelerate, policymakers need reliable ways…
Around the World in HTA: Japan – An algorithmic approach to containing costs
14 April 2026
Japan’s health technology assessment (HTA) system uses algorithmic drug…
Seven reflections on the UK EQ-5D-5L value set – and what comes next
30 March 2026
The long-awaited UK EQ-5D-5L value set has been published, marking a key moment…
Robust analysis, real-world problems
OHE research supports pragmatic solutions and stronger policy decisions
Areas of expertise
OHE’s expertise covers a wide range of topics
Health Technology Assessment (HTA)
Valuing patient and carer time in HTA: equity and opportunity cost
We address two criticisms of valuing patient and carer time in HTA: that it would displace health outcomes by misallocating…
The value of fast diagnostics in time-critical infections
Advancing earlier intervention in time‑critical infections Sepsis continues to impose a substantial global burden, with…
Drug Development/R&D
Is the revised Congressional Budget Office model of new drug development fit for purpose?
As U.S. drug-pricing policy changes accelerate, policymakers need reliable ways to understand how reduced pharmaceutical…
Evaluating novel antimicrobials within EU joint clinical assessments
Antimicrobial resistance (AMR) is a growing global health and economic threat. It is responsible for an additional 9.5…
Digital Health
The true cost and burden of frontotemporal dementia: Early insights into a pressing challenge
In recognition of Frontotemporal Dementia Awareness Week, OHE shares ongoing work quantifying the disease burden and…
OHE’s submission for the DHSC’s next 10 years of planning
This Insight summarises the recommendations OHE submitted towards the Department of Health & Social Care’s consultation…
Prevention
The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality globally, and is responsible…
Turning around the NHS: Reflections on the 2025 OHE Annual Lecture
In this year's Annual Lecture, Prof Anita Charlesworth takes a closer look at the NHS 10 Year Health Plan, concluding that…
Events
OHE events sharing innovation and insights
OHE at the World Health Assembly 2026
21 May 2026, 2:00pm
Join us in shaping the economics of health, prevention, and climate action
Mid-year health check: policy, pricing & what’s coming
17 June 2026, 2:00pm
Halfway through 2026, OHE takes stock. We reflect on the defining moments of the year so far and look ahead to the policy…
